Do analysts recommend CUE or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend TXMD or IBIO?

iBio has a consensus target price of $5.00, suggesting a potential upside of 198.51%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13

Which has better earnings & valuation, TXMD or IBIO?

TherapeuticsMD has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TherapeuticsMD $3.02M 8.88 -$570K $0.06 38.65 iBio $400K 208.04 -$18.38M -$0.58 N/A

Is TXMD or IBIO more profitable?

TherapeuticsMD has a net margin of 5.34% compared to iBio's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets TherapeuticsMD 5.34% 0.32% 0.23% iBio N/A -53.86% -46.48%

Do analysts rate TXMD or PMN?

Promis Neurosciences has a consensus target price of $26.50, indicating a potential upside of 153.56%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Do analysts prefer FTLF or TXMD?

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 100.65%. Given FitLife Brands' stronger consensus rating and higher probable upside, equities analysts clearly believe FitLife Brands is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

TherapeuticsMD (TXMD) Competitors

$2.32 +0.12 (+5.41%)

As of 01:54 PM Eastern

Compare

TXMD vs. CUE, IBIO, PMN, FTLF, and ATRA

Should you buy TherapeuticsMD stock or one of its competitors? MarketBeat compares TherapeuticsMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TherapeuticsMD include Cue Biopharma (CUE), iBio (IBIO), Promis Neurosciences (PMN), FitLife Brands (FTLF), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does TherapeuticsMD compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

TherapeuticsMD has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.88	-$26.60M	-$5.58	N/A
TherapeuticsMD	$3.02M	8.88	-$570K	$0.06	38.65

TherapeuticsMD has a net margin of 5.34% compared to Cue Biopharma's net margin of -59.65%. TherapeuticsMD's return on equity of 0.32% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
TherapeuticsMD	5.34%	0.32%	0.23%

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cue Biopharma has a beta of 2.51, meaning that its share price is 151% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Cue Biopharma's average media sentiment score of 1.87 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Cue Biopharma	Very Positive
TherapeuticsMD	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Cue Biopharma on 7 of the 11 factors compared between the two stocks.

How does TherapeuticsMD compare to iBio?

TherapeuticsMD (NASDAQ:TXMD) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

iBio has a consensus target price of $5.00, suggesting a potential upside of 198.51%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

TherapeuticsMD has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TherapeuticsMD has a net margin of 5.34% compared to iBio's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
iBio	N/A	-53.86%	-46.48%

In the previous week, iBio had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for iBio and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat iBio's score of 0.60 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
iBio	Positive

TherapeuticsMD has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.88	-$570K	$0.06	38.65
iBio	$400K	208.04	-$18.38M	-$0.58	N/A

Summary

TherapeuticsMD beats iBio on 9 of the 17 factors compared between the two stocks.

How does TherapeuticsMD compare to Promis Neurosciences?

TherapeuticsMD (NASDAQ:TXMD) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TherapeuticsMD has a net margin of 5.34% compared to Promis Neurosciences' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Promis Neurosciences	N/A	-237.99%	-151.04%

In the previous week, Promis Neurosciences had 10 more articles in the media than TherapeuticsMD. MarketBeat recorded 11 mentions for Promis Neurosciences and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat Promis Neurosciences' score of 0.75 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Promis Neurosciences	Positive

TherapeuticsMD has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.88	-$570K	$0.06	38.65
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Promis Neurosciences has a consensus target price of $26.50, indicating a potential upside of 153.56%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

TherapeuticsMD beats Promis Neurosciences on 10 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

FitLife Brands has higher revenue and earnings than TherapeuticsMD. FitLife Brands is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.24	$6.33M	$0.60	17.86
TherapeuticsMD	$3.02M	8.88	-$570K	$0.06	38.65

FitLife Brands has a net margin of 6.64% compared to TherapeuticsMD's net margin of 5.34%. FitLife Brands' return on equity of 18.31% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
TherapeuticsMD	5.34%	0.32%	0.23%

FitLife Brands has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

In the previous week, FitLife Brands had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for FitLife Brands and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat FitLife Brands' score of 0.93 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
FitLife Brands	Positive
TherapeuticsMD	Very Positive

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 100.65%. Given FitLife Brands' stronger consensus rating and higher probable upside, equities analysts clearly believe FitLife Brands is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 61.4% of FitLife Brands shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

FitLife Brands beats TherapeuticsMD on 11 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Atara Biotherapeutics currently has a consensus target price of $9.50, indicating a potential downside of 10.12%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Atara Biotherapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atara Biotherapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than TherapeuticsMD. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$0.67	N/A
TherapeuticsMD	$3.02M	8.88	-$570K	$0.06	38.65

TherapeuticsMD has a net margin of 5.34% compared to Atara Biotherapeutics' net margin of -40.91%. TherapeuticsMD's return on equity of 0.32% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
TherapeuticsMD	5.34%	0.32%	0.23%

In the previous week, Atara Biotherapeutics had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat Atara Biotherapeutics' score of 0.51 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
TherapeuticsMD	Very Positive

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Atara Biotherapeutics and TherapeuticsMD tied by winning 8 of the 16 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.83M	$2.99B	$6.48B	$12.37B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	38.65	18.52	23.96	24.65
Price / Sales	8.88	461.99	537.15	167.03
Price / Cash	47.15	55.88	27.48	37.92
Price / Book	1.00	4.01	10.46	6.81
Net Income	-$570K	$75.79M	$3.56B	$337.32M
7 Day Performance	23.36%	2.08%	1.04%	2.37%
1 Month Performance	15.96%	-0.24%	2.01%	4.25%
1 Year Performance	98.21%	23.67%	25.87%	32.60%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	1.479 of 5 stars	$2.32 +5.4%	N/A	+88.0%	$26.83M	$3.02M	38.65	420	Positive News
CUE Cue Biopharma	0.3634 of 5 stars	$28.62 +18.9%	N/A	-95.5%	$97.36M	$27.47M	N/A	60	Positive News
IBIO iBio	4.0226 of 5 stars	$1.76 -6.9%	$4.75 +169.9%	N/A	$93.89M	$400K	N/A	100
PMN Promis Neurosciences	4.0409 of 5 stars	$10.15 -2.5%	$26.50 +161.1%	-20.3%	$93.35M	N/A	N/A	5
FTLF FitLife Brands	4.5324 of 5 stars	$9.72 -1.9%	$21.50 +121.2%	-21.4%	$93.07M	$81.46M	16.09	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. CUE, IBIO, PMN, FTLF, and ATRA

How does TherapeuticsMD compare to Cue Biopharma?

Summary

How does TherapeuticsMD compare to iBio?

Summary

How does TherapeuticsMD compare to Promis Neurosciences?

Summary

How does TherapeuticsMD compare to FitLife Brands?

Summary

How does TherapeuticsMD compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. CUE, IBIO, PMN, FTLF, and ATRA

How does TherapeuticsMD compare to Cue Biopharma?

Which has stronger valuation and earnings, CUE or TXMD?

Is CUE or TXMD more profitable?

Do institutionals & insiders hold more shares of CUE or TXMD?

Which has more risk and volatility, CUE or TXMD?

Does the media refer more to CUE or TXMD?

Do analysts recommend CUE or TXMD?

Summary

How does TherapeuticsMD compare to iBio?

Do analysts recommend TXMD or IBIO?

Which has more risk and volatility, TXMD or IBIO?

Do insiders & institutionals hold more shares of TXMD or IBIO?

Is TXMD or IBIO more profitable?

Does the media refer more to TXMD or IBIO?

Which has better earnings & valuation, TXMD or IBIO?

Summary

How does TherapeuticsMD compare to Promis Neurosciences?

Do insiders and institutionals have more ownership in TXMD or PMN?

Is TXMD or PMN more profitable?

Does the media favor TXMD or PMN?

Which has more risk and volatility, TXMD or PMN?

Which has higher valuation & earnings, TXMD or PMN?

Do analysts rate TXMD or PMN?

Summary

How does TherapeuticsMD compare to FitLife Brands?

Which has better valuation and earnings, FTLF or TXMD?

Is FTLF or TXMD more profitable?

Which has more risk and volatility, FTLF or TXMD?

Does the media refer more to FTLF or TXMD?

Do analysts prefer FTLF or TXMD?

Do insiders & institutionals believe in FTLF or TXMD?

Summary

How does TherapeuticsMD compare to Atara Biotherapeutics?

Do analysts prefer ATRA or TXMD?

Which has more volatility and risk, ATRA or TXMD?

Which has higher earnings & valuation, ATRA or TXMD?

Is ATRA or TXMD more profitable?

Does the media refer more to ATRA or TXMD?

Do insiders and institutionals believe in ATRA or TXMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools